Hologic Reaches New 52-Week High (HOLX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Hologic (Nasdaq: HOLX) hit a new 52-week high Thursday as it is currently trading at $23.95, above its previous 52-week high of $23.93 with 963,348 shares traded as of 2:41 p.m. ET. Average volume has been 2.9 million shares over the past 30 days.

Hologic has a market cap of $6.32 billion and is part of the health care sector and health services industry. Shares are up 18.1% year to date as of the close of trading on Wednesday.

Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for the healthcare needs of women.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Hologic Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Hologic Looks Good on the Charts

Five S&P 500 Boards Have No Women as Gender Balance Growth Stalls

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Cramer: These Sectors Look Bullish (Part III)